Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $62.25

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $62.25.

A number of equities research analysts recently weighed in on CLDX shares. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Citigroup began coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday.

Celldex Therapeutics Stock Down 0.9 %

Shares of Celldex Therapeutics stock opened at $26.22 on Friday. Celldex Therapeutics has a 12-month low of $24.43 and a 12-month high of $53.18. The business’s 50 day moving average is $33.60 and its 200-day moving average is $35.80. The stock has a market cap of $1.74 billion, a P/E ratio of -10.20 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. On average, sell-side analysts expect that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Several large investors have recently modified their holdings of CLDX. KBC Group NV grew its holdings in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Celldex Therapeutics during the 2nd quarter worth $76,000. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics during the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co grew its holdings in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.